3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
402
Rectal Neoplasms
151
Colonic Neoplasms
148
Pancreatic Neoplasms
113
Stomach Neoplasms
106
Neoplasm Metastasis
88
Neoplasms
74
Esophageal Neoplasms
59
Small Cell Lung Carcinoma
44
Neuroblastoma
42
Lung Neoplasms
42
Glioblastoma
38
Carcinoma, Non-Small-Cell Lung
37
Esophageal Squamous Cell Carcinoma
33
Brain Neoplasms
33
Unspecified Adult Solid Tumor, Protocol Specific
31
Glioma
31
Breast Neoplasms
28
Central Nervous System Neoplasms
27
Adenocarcinoma Of Esophagus
27
Sarcoma
26
Gliosarcoma
22
Astrocytoma
22
Rhabdomyosarcoma
21
Sarcoma, Ewing
18
Adenocarcinoma
18
Gastrointestinal Neoplasms
17
Oligodendroglioma
16
Cholangiocarcinoma
14
Recurrence
13
Interventions
pembrolizumab
5
Oxaliplatin
3
Nivolumab
3
sintilimab
2
Leucovorin
2
Immune Checkpoint Inhibitors
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
relatlimab
1
regorafenib
1
epacadostat
1
dabrafenib
1
copanlisib
1
binimetinib
1
atezolizumab
1
Tiragolumab
1
Irinotecan
1
Fulvestrant
1
E7046
1
Cetuximab
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Spinocerebellar Degenerations
×
Irinotecan
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts